These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31720558)

  • 21. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
    Thaçi D; Eyerich K; Pinter A; Sebastian M; Unnebrink K; Rubant S; Williams DA; Weisenseel P
    Br J Dermatol; 2022 Jan; 186(1):30-39. PubMed ID: 33991341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
    Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tildrakizumab: A Review of Phase II and III Clinical Trials.
    Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
    Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
    Torres T
    Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
    Crowley JJ; Warren RB; Cather JC
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis.
    Heim J; Vasquez JG; Bhutani T; Koo J; Mathew J; Gogineni R; Ferro T; Bhatia N
    J Drugs Dermatol; 2024 Aug; 23(8):612-618. PubMed ID: 39093661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
    Li L; Wu Z; Wu M; Qiu X; Wu Y; Kuang Z; Wang L; Sun T; Liu Y; Yi S; Jing H; Zhou S; Chen B; Wu D; Wu W; Liu J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107008. PubMed ID: 33069927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
    Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
    J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risankizumab in Adults with Psoriatic Arthritis.
    Machlab K; Yeung J; Gooderham M
    Skin Therapy Lett; 2023 Nov; 28(6):1-6. PubMed ID: 38015960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
    Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
    J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
    Suleiman AA; Khatri A; Oberoi RK; Othman AA
    Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
    Pang Y; Khatri A; Suleiman AA; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 39. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.
    Khatri A; Suleiman AA; Polepally AR; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):378-387. PubMed ID: 31355921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.